Journal for ImmunoTherapy of Cancer (Feb 2023)

BRCA1 deficiency in mature CD8+ T lymphocytes impairs antitumor immunity

  • Rong Li,
  • Xiaowen Zhang,
  • Bogang Wu,
  • Yanfen Hu,
  • Anelia Horvath,
  • Claudine Isaacs,
  • Yidong Chen,
  • Leilei Qi,
  • Huai-Chin Chiang,
  • Haihui Pan,
  • Alexandra Greenbaum,
  • Elizabeth Stark,
  • Li-Ju Wang,
  • Bassem R. Haddad,
  • Dionyssia Clagett,
  • Richard Elledge

DOI
https://doi.org/10.1136/jitc-2022-005852
Journal volume & issue
Vol. 11, no. 2

Abstract

Read online

Women with BRCA1 germline mutations have approximately an 80% lifetime chance of developing breast cancer. While the tumor suppressor function of BRCA1 in breast epithelium has been studied extensively, it is not clear whether BRCA1 deficiency in non-breast somatic cells also contribute to tumorigenesis. Here, we report that mouse Brca1 knockout (KO) in mature T lymphocytes compromises host antitumor immune response to transplanted syngeneic mouse mammary tumors. T cell adoptive transfer further corroborates CD8+ T cell-intrinsic impact of Brca1 KO on antitumor adaptive immunity. T cell-specific Brca1 KO mice exhibit fewer total CD8+, more exhausted, reduced cytotoxic, and reduced memory tumor-infiltrating T cell populations. Consistent with the preclinical data, cancer-free BRCA1 mutation-carrying women display lower abundance of circulating CD8+ lymphocytes than the age-matched control group. Thus, our findings support the notion that BRCA1 deficiency in adaptive immunity could contribute to BRCA1-related tumorigenesis. We also suggest that prophylactic boosting of adaptive immunity may reduce cancer incidence among at-risk women.